133 related articles for article (PubMed ID: 2249982)
1. Anionic site interactions in human butyrylcholinesterase disrupted by two single point mutations.
Neville LF; Gnatt A; Padan R; Seidman S; Soreq H
J Biol Chem; 1990 Dec; 265(34):20735-8. PubMed ID: 2249982
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular relationships in cholinesterases revealed by oocyte expression of site-directed and natural variants of human BCHE.
Neville LF; Gnatt A; Loewenstein Y; Seidman S; Ehrlich G; Soreq H
EMBO J; 1992 Apr; 11(4):1641-9. PubMed ID: 1373381
[TBL] [Abstract][Full Text] [Related]
3. Aspartate-70 to glycine substitution confers resistance to naturally occurring and synthetic anionic-site ligands on in-ovo produced human butyrylcholinesterase.
Neville LF; Gnatt A; Loewenstein Y; Soreq H
J Neurosci Res; 1990 Dec; 27(4):452-60. PubMed ID: 2079709
[TBL] [Abstract][Full Text] [Related]
4. Site-directed mutagenesis of active site residues reveals plasticity of human butyrylcholinesterase in substrate and inhibitor interactions.
Gnatt A; Loewenstein Y; Yaron A; Schwarz M; Soreq H
J Neurochem; 1994 Feb; 62(2):749-55. PubMed ID: 8294937
[TBL] [Abstract][Full Text] [Related]
5. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
6. Pesticide poisoning, succinylcholine-induced apnea, and pseudocholinesterase.
Nelson TC; Burritt MF
Mayo Clin Proc; 1986 Sep; 61(9):750-2. PubMed ID: 3747617
[No Abstract] [Full Text] [Related]
7. Characterization of a novel butyrylcholinesterase point mutation (p.Ala34Val), "silent" with mivacurium.
Delacour H; Lushchekina S; Mabboux I; Ceppa F; Masson P; Schopfer LM; Lockridge O
Biochem Pharmacol; 2014 Dec; 92(3):476-83. PubMed ID: 25264279
[TBL] [Abstract][Full Text] [Related]
8. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
Loewenstein-Lichtenstein Y; Glick D; Gluzman N; Sternfeld M; Zakut H; Soreq H
Mol Pharmacol; 1996 Dec; 50(6):1423-31. PubMed ID: 8967962
[TBL] [Abstract][Full Text] [Related]
9. Asp7O in the peripheral anionic site of human butyrylcholinesterase.
Masson P; Froment MT; Bartels CF; Lockridge O
Eur J Biochem; 1996 Jan; 235(1-2):36-48. PubMed ID: 8631355
[TBL] [Abstract][Full Text] [Related]
10. Identification of human plasma cholinesterase variants in 6,688 individuals using biochemical analysis.
Jensen FS; Skovgaard LT; Viby-Mogensen J
Acta Anaesthesiol Scand; 1995 Feb; 39(2):157-62. PubMed ID: 7793180
[TBL] [Abstract][Full Text] [Related]
11. Sheep brain pseudocholinesterase: inhibition kinetics of the partially purified enzyme by some substrate analogues.
Cokuğraş AN; Tezcan EF
Chem Biol Interact; 1993 Jun; 87(1-3):259-64. PubMed ID: 8343984
[TBL] [Abstract][Full Text] [Related]
12. Concordance of butyrylcholinesterase phenotype with genotype: implications for biochemical reporting.
Parnas ML; Procter M; Schwarz MA; Mao R; Grenache DG
Am J Clin Pathol; 2011 Feb; 135(2):271-6. PubMed ID: 21228368
[TBL] [Abstract][Full Text] [Related]
13. Frequency of butyrylcholinesterase gene mutations in individuals with abnormal inhibition numbers: an Italian-population study.
Lando G; Mosca A; Bonora R; Azzario F; Penco S; Marocchi A; Panteghini M; Patrosso MC
Pharmacogenetics; 2003 May; 13(5):265-70. PubMed ID: 12724618
[TBL] [Abstract][Full Text] [Related]
14. Prolonged response to succinylcholine: a new variant of plasma cholinesterase that is identified as normal by traditional phenotyping methods.
Greenberg CP; Primo-Parmo SL; Pantuck EJ; la Du BN
Anesth Analg; 1995 Aug; 81(2):419-21. PubMed ID: 7618741
[No Abstract] [Full Text] [Related]
15. Dibucaine inhibition of serum cholinesterase.
Elamin B
J Biochem Mol Biol; 2003 Mar; 36(2):149-53. PubMed ID: 12689511
[TBL] [Abstract][Full Text] [Related]
16. Role of aspartate 70 and tryptophan 82 in binding of succinyldithiocholine to human butyrylcholinesterase.
Masson P; Legrand P; Bartels CF; Froment MT; Schopfer LM; Lockridge O
Biochemistry; 1997 Feb; 36(8):2266-77. PubMed ID: 9047329
[TBL] [Abstract][Full Text] [Related]
17. Importance of aspartate-70 in organophosphate inhibition, oxime re-activation and aging of human butyrylcholinesterase.
Masson P; Froment MT; Bartels CF; Lockridge O
Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):53-61. PubMed ID: 9224629
[TBL] [Abstract][Full Text] [Related]
18. [Cholinesterases].
Lejus C; Blanloeil Y; Burnat P; Souron R
Ann Fr Anesth Reanim; 1998; 17(9):1122-35. PubMed ID: 9835982
[TBL] [Abstract][Full Text] [Related]
19. The pseudocholinesterase variants. Esterase levels and dibucaine numbers in families selected through suxamethonium sensitive individuals.
HARRIS H; WHITTAKER M; LEHMANN H; SILK E
Acta Genet Stat Med; 1960; 10():1-16. PubMed ID: 14399955
[No Abstract] [Full Text] [Related]
20. Expression of alternatively terminated unusual human butyrylcholinesterase messenger RNA transcripts, mapping to chromosome 3q26-ter, in nervous system tumors.
Gnatt A; Prody CA; Zamir R; Lieman-Hurwitz J; Zakut H; Soreq H
Cancer Res; 1990 Apr; 50(7):1983-7. PubMed ID: 2317787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
